whether patients need additional monitoring if they're switched from Coumadin to one of the generics
October 2001
There's a lot of confusion about whether patients need additional monitoring if they're switched from Coumadin to one of the generics.
A recent labelling change for warfarin removed the recommendation to monitor prothrombin when switching from Coumadin.
Taro is promoting that this means no additional INR testing is needed when patients are switched to Taro-warfarin.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote